A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance

Trial Profile

A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DEAP
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 29 Dec 2012 Planned patient number is 1000 according to European Clinical Trials Database record.
    • 29 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001646-16).
    • 29 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top